Can eye injections stop wet AMD before it starts?

NCT ID NCT02462889

Completed Prevention Sponsor: Jeffrey S Heier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injections of aflibercept (Eylea) into the eye could prevent the development of wet age-related macular degeneration (AMD) in people at high risk. 128 participants with early signs of AMD in one eye and wet AMD in the other eye received either Eylea or a sham injection. The main goal was to see if Eylea could reduce the chance of the high-risk eye converting to wet AMD over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aflibercept (Eylea)
What this could lead to: If successful, this could point toward a preventive treatment for wet AMD in people at high risk, potentially saving vision.
What could go wrong: This is a small, early-phase trial with only 128 participants. The results may not apply to everyone, and the treatment involves regular eye injections with risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

NJ Retina

Edison, New Jersey, 08817, United States
Ophthalmic Consultants of Boston

Boston, Massachusetts, 02114, United States
Retina Consultants of Houston

Houston, Texas, 77030, United States
Retina-Vitreous Associates Medical Group

Beverly Hills, California, 90211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.